JP7454573B2 - インスリン抵抗性を処置するためのｓｈｐ２阻害剤の使用 - Google Patents

インスリン抵抗性を処置するためのｓｈｐ２阻害剤の使用 Download PDF

Info

Publication number
JP7454573B2
JP7454573B2 JP2021526584A JP2021526584A JP7454573B2 JP 7454573 B2 JP7454573 B2 JP 7454573B2 JP 2021526584 A JP2021526584 A JP 2021526584A JP 2021526584 A JP2021526584 A JP 2021526584A JP 7454573 B2 JP7454573 B2 JP 7454573B2
Authority
JP
Japan
Prior art keywords
shp2
subject
treatment
refers
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021526584A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022509609A5 (https=
JPWO2020104635A5 (https=
JP2022509609A (ja
Inventor
ヤート，アルメル
パク，ロマン
タジャン，ミレーヌ
プラドール，ジャン－フィリップ
バレ，フィリップ
ドレイ，セドリック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Toulouse
Original Assignee
Universite Toulouse III Paul Sabatier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Toulouse III Paul Sabatier filed Critical Universite Toulouse III Paul Sabatier
Publication of JP2022509609A publication Critical patent/JP2022509609A/ja
Publication of JP2022509609A5 publication Critical patent/JP2022509609A5/ja
Publication of JPWO2020104635A5 publication Critical patent/JPWO2020104635A5/ja
Application granted granted Critical
Publication of JP7454573B2 publication Critical patent/JP7454573B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021526584A 2018-11-23 2019-11-22 インスリン抵抗性を処置するためのｓｈｐ２阻害剤の使用 Active JP7454573B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18306558 2018-11-23
EP18306558.0 2018-11-23
PCT/EP2019/082180 WO2020104635A1 (en) 2018-11-23 2019-11-22 Use of shp2 inhibitors for the treatment of insulin resistance

Publications (4)

Publication Number Publication Date
JP2022509609A JP2022509609A (ja) 2022-01-21
JP2022509609A5 JP2022509609A5 (https=) 2022-09-28
JPWO2020104635A5 JPWO2020104635A5 (https=) 2022-09-28
JP7454573B2 true JP7454573B2 (ja) 2024-03-22

Family

ID=64664217

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021526584A Active JP7454573B2 (ja) 2018-11-23 2019-11-22 インスリン抵抗性を処置するためのｓｈｐ２阻害剤の使用

Country Status (4)

Country Link
US (2) US20220000869A1 (https=)
EP (1) EP3883574A1 (https=)
JP (1) JP7454573B2 (https=)
WO (1) WO2020104635A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL299131A (en) 2020-06-18 2023-02-01 Revolution Medicines Inc Methods for delaying, preventing and treating acquired resistance to RAS inhibitors
MX2023002248A (es) 2020-09-03 2023-05-16 Revolution Medicines Inc Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2.
MX2023003060A (es) 2020-09-15 2023-04-05 Revolution Medicines Inc Derivados indolicos como inhibidores de ras en el tratamiento del cancer.
CA3217393A1 (en) 2021-05-05 2022-11-10 Elena S. Koltun Ras inhibitors
AU2022268962A1 (en) 2021-05-05 2023-12-14 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
WO2022235866A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
CN119136806A (zh) 2022-03-08 2024-12-13 锐新医药公司 用于治疗免疫难治性肺癌的方法
EP4496566A1 (en) * 2022-03-21 2025-01-29 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of shp2 inhibitors for inhibiting senescence
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
CN117625770A (zh) * 2022-08-26 2024-03-01 上海交通大学 Ptpn11基因作为靶点在制备治疗药源性代谢综合征药物中的应用
EP4687905A1 (en) 2023-03-30 2026-02-11 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
KR20260005904A (ko) 2023-04-07 2026-01-12 레볼루션 메디슨즈, 인크. 매크로사이클릭 ras 억제제
CN121263418A (zh) 2023-04-07 2026-01-02 锐新医药公司 大环ras抑制剂
AU2024252105A1 (en) 2023-04-14 2025-10-16 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
KR20250172857A (ko) 2023-04-14 2025-12-09 레볼루션 메디슨즈, 인크. Ras 억제제의 결정형
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
IL326136A (en) 2023-08-07 2026-03-01 Revolution Medicines Inc RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002506055A (ja) 1998-03-12 2002-02-26 ノボ ノルディスク アクティーゼルスカブ タンパク質チロシンホスファターゼ（ｐｔｐアーゼ）の調節剤
JP2005516061A (ja) 2002-01-29 2005-06-02 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ タンパク質チロシンホスファターゼの調節因子としての置換メチレンアミド誘導体
US20080058431A1 (en) 2004-03-26 2008-03-06 Gen-Sheng Feng Modulators of Shp2 Tyrosine Phosphatase and Their Use in the Treatment of Body Weight Disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566131B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of Smad6 expression
US6410323B1 (en) 1999-08-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense modulation of human Rho family gene expression
US6107091A (en) 1998-12-03 2000-08-22 Isis Pharmaceuticals Inc. Antisense inhibition of G-alpha-16 expression
US5981732A (en) 1998-12-04 1999-11-09 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-13 expression
US6046321A (en) 1999-04-09 2000-04-04 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-i1 expression
US6365354B1 (en) 2000-07-31 2002-04-02 Isis Pharmaceuticals, Inc. Antisense modulation of lysophospholipase I expression
US6566135B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 6 expression
US7399586B2 (en) * 2002-05-23 2008-07-15 Ceptyr, Inc. Modulation of biological signal transduction by RNA interference
WO2007117699A2 (en) 2006-04-07 2007-10-18 University Of South Florida Inhibition of shp2/ptpn11 protein tyrosine phosphatase by nsc-87877, nsc-117199 and their analogs
WO2010121212A2 (en) 2009-04-17 2010-10-21 H. Lee Moffit Cancer Center And Research Institute, Inc. Indoline scaffold shp-2 inhibitors and method of treating cancer
EP3016652A4 (en) 2013-07-03 2017-03-08 Indiana University Research and Technology Corporation Shp2 inhibitors and methods of treating autoimmune and/or glomerulonephritis-associated diseases using shp2 inhibitors
US9932288B2 (en) 2015-12-09 2018-04-03 West Virginia University Chemical compound for inhibition of SHP2 function and for use as an anti-cancer agent
NL2019390B1 (en) * 2017-08-04 2019-02-21 Univ Leiden Screening Method
US11426422B2 (en) * 2018-01-30 2022-08-30 Research Development Foundation SHP2 inhibitors and methods of use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002506055A (ja) 1998-03-12 2002-02-26 ノボ ノルディスク アクティーゼルスカブ タンパク質チロシンホスファターゼ（ｐｔｐアーゼ）の調節剤
JP2005516061A (ja) 2002-01-29 2005-06-02 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ タンパク質チロシンホスファターゼの調節因子としての置換メチレンアミド誘導体
US20080058431A1 (en) 2004-03-26 2008-03-06 Gen-Sheng Feng Modulators of Shp2 Tyrosine Phosphatase and Their Use in the Treatment of Body Weight Disorders

Also Published As

Publication number Publication date
WO2020104635A1 (en) 2020-05-28
US20220000869A1 (en) 2022-01-06
JP2022509609A (ja) 2022-01-21
US20250090529A1 (en) 2025-03-20
EP3883574A1 (en) 2021-09-29

Similar Documents

Publication Publication Date Title
JP7454573B2 (ja) インスリン抵抗性を処置するためのｓｈｐ２阻害剤の使用
US11426422B2 (en) SHP2 inhibitors and methods of use thereof
JP7381471B2 (ja) 脱髄疾患の治療
El-Lithy et al. Prophylactic L-arginine and ibuprofen delay the development of tactile allodynia and suppress spinal miR-155 in a rat model of diabetic neuropathy
US20230277559A1 (en) Compositions and Methods for the Treatment of Inflammation in Urological Pathology
KR20170104597A (ko) 신경근육, 신경퇴행, 자가면역, 발달 및/또는 대사 질환의 치료를 위한 뇌 유도된 신경친화성 인자(bdnf)의 유도된 발현
JP2020503327A (ja) Ｓｍａｄ７アンチセンスオリゴヌクレオチドの組成物および乾癬を処置するまたは予防する方法
US20150328186A1 (en) Methods of Treating Hepatic Fibrosis and Associated Diseases by Regulating Rev-ERB Activity
Li et al. Mitigating ibrutinib‐induced ventricular arrhythmia and cardiac dysfunction with metformin
US8247389B2 (en) Treatment of scleroderma
WO2021236789A1 (en) Method of treating obesity-induced glucose intolerance and liver fibrosis
TWI565480B (zh) 羽扇豆醇醋酸酯微脂體及其用於製備抑制蝕骨細胞生成藥物的應用
US20240238268A1 (en) Treatments and methods for treating alzheimer's disease
JP2025538360A (ja) 阻害性核酸およびその使用方法
TWI795529B (zh) 肌動蛋白解聚劑用於治療焦慮疾患之用途
WO2018172570A1 (en) Gfi1 inhibitors for the treatment of hyperglycemia
CA3239517A1 (en) Antisense oligonucleotide for use in the treatment of psoriasis-induced itching and phospholipid vesicle comprising said oligonucleotide
Maler et al. Intermittent fasting reduces glaucomatous damage in an HSP27 autoimmune mouse model
EA052514B1 (ru) Антисмысловой олигонуклеотид для применения для лечения индуцируемого псориазом зуда и фосфолипидная везикула, содержащая указанный олигонуклеотид
WO2026057679A1 (en) Inhibitor of rab30 for use in a method of treatment of metabolic dysfunction-associated steatotic liver disease (masld)
TW202519221A (zh) Ｗｅｅ１抑制劑及ｐｋｍｙｔ１抑制劑之組合
WO2025182103A1 (ja) 脳梗塞の機能予後改善用組成物
EP4496566A1 (en) Use of shp2 inhibitors for inhibiting senescence
CN115916164A (zh) 用髓过氧化物酶抑制剂治疗肌萎缩侧索硬化症的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220916

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220916

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230831

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231204

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240220

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240311

R150 Certificate of patent or registration of utility model

Ref document number: 7454573

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150